The PI3K inhibitor LY294002 was added to BLM-treated A549 cells, and the cells became less fibroblast-like and tended to appear more like normal cells (Figure 5C), suggesting that PI3K/Akt pathway is important target candidate for lung fibrosis treatment or prevention. This evidence concerns the gene AKT1 and pulmonary fibrosis.